Personalis, Inc. Website

Personalis, Inc.

NasdaqGM-PSNL

Company Overview

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

  • Name

    Personalis, Inc.

  • CEO

    Christopher Hall

  • Website

    www.personalis.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    2011

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 13, 2025 - Dec 13, 2025

Personalis Inc. Surges Amid Medicare Rate Announcement Despite Insider Selling Concerns

  • Major catalyst for growth: Medicare reimbursement rates for NeXT Personal cancer tests announced, boosting investor confidence.
  • Insider selling by COO raises skepticism about management's outlook and future growth potential.
  • Strategic financial maneuvers include filing to sell up to $100 million while maintaining strong cash reserves.

Over the past month, Personalis Inc. (PSNL) has recorded a significant increase of 9.4%. This performance stands in stark contrast to the S&P 500, which experienced a decline of 0.2%, resulting in an outperformance of 9.6% relative to this benchmark index. Additionally, PSNL surpassed the Health Care sector (XLV), which underperformed by 8.5%, highlighting its resilience amid broader market challenges.

A pivotal factor contributing to PSNL's positive momentum was the announcement regarding Medicare reimbursement rates for its NeXT Personal cancer surveillance tests on November 25th. The established rates—$4,266 for breast cancer monitoring and $1,164 for plasma tests—were well-received as they are expected to enhance profit margins going forward. Following this news, shares rose over 11% on two separate occasions around the announcement date.

However, not all developments were favorable during this period; substantial insider selling raised concerns among investors about future prospects and management's confidence in ongoing operations or growth potential. On December 1st and again on November 26th, COO Tachibana sold shares totaling over $1 million combined.

Furthermore, discussions surrounding strategic financial moves added complexity to PSNL’s narrative as reports indicated that it filed to sell up to $100 million through an at-the-market program while holding approximately $150 million in cash reserves—suggesting a proactive stance despite some bearish sentiment stemming from these actions.

The acquisition of Foresight Diagnostics by Natera also influenced investor perceptions concerning PSNL's intellectual property settlement with Foresight—a development viewed negatively due to potential additional fees related to their agreement if certain conditions arise following Natera's integration plans announced earlier this month.

Overall, while fluctuations occurred due both positive advancements and negative sentiments surrounding insider trading along with competitive dynamics within oncology diagnostics markets, Personalis Inc.'s overall performance remained robust throughout the month compared with broader indices like the S&P 500 and its sector peers.

NasdaqGM:PSNL